How do you approach ADT in patients with high-risk prostate cancer who have risk factors for VTE, such as Factor V Leiden?

My default recommendation for patients with localized, high-risk prostate cancer is to recommend the use of long-term ADT. This intervention seems to offer a relatively large, clinically significant OS benefit for patients in the modern era receiving dose-escalated ADT. This benefit has been observe...